Johnson & Johnson (JNJ) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-28..
- Stock-based compensation / revenue · 12 months: Value 1.44%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-28..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.44% | Share-based compensation / revenue. Period ending 2026-06-28. $1.41B ÷ $97.93B × 100 ≈ 1.44% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 97.93B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.41B USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | $97.93B | $1.41B | (m) | (m) | (m) | 1.44% | (m) | (m) |
| 2026-03-29 | (m) | $96.36B | $1.37B | (m) | (m) | (m) | 1.42% | (m) | (m) |
| 2025-12-28 | $109.00M | $94.19B | $1.35B | (m) | (m) | 0.12% | 1.44% | (m) | (m) |
| 2025-09-28 | (m) | $92.15B | $1.28B | (m) | (m) | (m) | 1.39% | (m) | (m) |
| 2025-06-29 | (m) | $90.63B | $1.23B | (m) | (m) | (m) | 1.36% | (m) | (m) |
| 2025-03-30 | (m) | $89.33B | $1.16B | (m) | (m) | (m) | 1.30% | (m) | (m) |
| 2024-12-29 | $1.84B | $88.82B | $1.18B | (m) | (m) | 2.07% | 1.32% | (m) | (m) |
| 2024-09-29 | (m) | $87.70B | $1.12B | (m) | (m) | (m) | 1.27% | (m) | (m) |
| 2024-06-30 | (m) | $86.58B | $1.12B | (m) | (m) | (m) | 1.29% | (m) | (m) |
| 2024-03-31 | (m) | $85.65B | $1.16B | (m) | $715.00M | (m) | 1.35% | (m) | Reported |
| 2023-12-31 | $483.00M | $85.16B | $1.16B | (m) | $772.00M | 0.57% | 1.36% | (m) | Reported |
| 2023-10-01 | (m) | $98.66B | $1.20B | (m) | $798.00M | (m) | 1.21% | (m) | Reported |
| 2023-07-02 | (m) | $97.77B | $1.18B | (m) | $789.00M | (m) | 1.21% | (m) | Reported |
| 2023-04-02 | (m) | $96.26B | $1.17B | (m) | $481.00M | (m) | 1.21% | (m) | Reported |
| 2023-01-01 | (m) | $94.94B | $1.14B | (m) | $276.00M | (m) | 1.20% | (m) | Reported |
| 2022-10-02 | (m) | $96.04B | $1.14B | (m) | $159.00M | (m) | 1.19% | (m) | Reported |
| 2022-07-03 | (m) | $95.59B | $1.12B | (m) | $128.00M | (m) | 1.17% | (m) | Reported |
| 2022-04-03 | (m) | $94.88B | $1.11B | (m) | $130.00M | (m) | 1.17% | (m) | Reported |
| 2022-01-02 | (m) | $93.78B | $1.14B | (m) | $183.00M | (m) | 1.21% | (m) | Reported |
| 2021-10-03 | (m) | $91.45B | $1.08B | (m) | $210.00M | (m) | 1.18% | (m) | Reported |
| 2021-07-04 | (m) | $89.19B | $1.08B | (m) | $234.00M | (m) | 1.21% | (m) | Reported |
| 2021-04-04 | (m) | $84.21B | $1.05B | (m) | $239.00M | (m) | 1.25% | (m) | Reported |
| 2021-01-03 | (m) | $82.58B | $1.00B | (m) | $201.00M | (m) | 1.22% | (m) | Reported |
| 2020-09-27 | (m) | $80.86B | $1.00B | (m) | $199.00M | (m) | 1.24% | (m) | Reported |
| 2020-06-28 | (m) | $80.50B | $994.00M | (m) | $203.00M | (m) | 1.23% | (m) | Reported |
| 2020-03-29 | (m) | $82.73B | $982.00M | (m) | $241.00M | (m) | 1.19% | (m) | Reported |
| 2019-12-29 | (m) | $82.06B | $977.00M | (m) | $318.00M | (m) | 1.19% | (m) | Reported |
| 2019-09-29 | (m) | $81.71B | $973.00M | (m) | $483.00M | (m) | 1.19% | (m) | Reported |
| 2019-06-30 | (m) | $81.33B | $970.00M | (m) | $678.00M | (m) | 1.19% | (m) | Reported |
| 2019-03-31 | (m) | $81.59B | $968.00M | (m) | $848.00M | (m) | 1.19% | (m) | Reported |
| 2018-12-30 | (m) | $81.58B | $978.00M | (m) | $1.00B | (m) | 1.20% | (m) | Reported |
| 2018-09-30 | (m) | (m) | $1.03B | (m) | $1.03B | (m) | (m) | (m) | Reported |
| 2018-07-01 | (m) | (m) | $1.02B | (m) | $1.01B | (m) | (m) | (m) | Reported |
| 2018-04-01 | (m) | (m) | $1.00B | (m) | $989.00M | (m) | (m) | (m) | Reported |
| 2017-12-31 | (m) | (m) | $962.00M | (m) | $934.00M | (m) | (m) | (m) | Reported |
| 2017-10-01 | (m) | (m) | $932.00M | (m) | $844.00M | (m) | (m) | (m) | Reported |
| 2017-07-02 | (m) | (m) | $921.00M | (m) | $807.00M | (m) | (m) | (m) | Reported |
| 2017-04-02 | (m) | (m) | $902.00M | (m) | $770.00M | (m) | (m) | (m) | Reported |
| 2017-01-01 | (m) | (m) | $878.00M | (m) | $726.00M | (m) | (m) | (m) | Reported |
| 2016-10-02 | (m) | (m) | $901.00M | (m) | $702.00M | (m) | (m) | (m) | Reported |
| 2016-07-03 | (m) | (m) | $879.00M | (m) | $633.00M | (m) | (m) | (m) | Reported |
| 2016-04-03 | (m) | (m) | $875.00M | (m) | $574.00M | (m) | (m) | (m) | Reported |
| 2016-01-03 | (m) | (m) | $874.00M | (m) | $552.00M | (m) | (m) | (m) | Reported |
| 2015-09-27 | (m) | (m) | $823.00M | (m) | $531.00M | (m) | (m) | (m) | Reported |
| 2015-06-28 | (m) | (m) | $826.00M | (m) | $538.00M | (m) | (m) | (m) | Reported |
| 2015-03-29 | (m) | (m) | $798.00M | $21.77B | $535.00M | (m) | (m) | 40.68× | Reported |
| 2014-12-28 | (m) | (m) | $792.00M | $21.59B | $533.00M | (m) | (m) | 40.51× | Reported |
| 2014-09-28 | (m) | (m) | $790.00M | $21.62B | $528.00M | (m) | (m) | 40.94× | Reported |
| 2014-06-29 | (m) | (m) | $745.00M | $18.43B | $503.00M | (m) | (m) | 36.65× | Reported |
| 2014-03-30 | (m) | (m) | $732.00M | $17.58B | $493.00M | (m) | (m) | 35.66× | Reported |
| 2013-12-29 | (m) | (m) | $728.00M | $16.41B | $482.00M | (m) | (m) | 34.05× | Reported |
| 2013-09-29 | (m) | (m) | $731.00M | $16.72B | $455.00M | (m) | (m) | 36.74× | Reported |
| 2013-06-30 | (m) | (m) | $716.00M | $16.67B | $485.00M | (m) | (m) | 34.37× | Reported |
| 2013-03-31 | (m) | (m) | $683.00M | $14.31B | $510.00M | (m) | (m) | 28.05× | Reported |
| 2012-12-30 | (m) | (m) | $662.00M | $14.96B | $532.00M | (m) | (m) | 28.11× | Reported |
| 2012-09-30 | (m) | (m) | $652.00M | $12.46B | $608.00M | (m) | (m) | 20.50× | Reported |
| 2012-07-01 | (m) | (m) | $651.00M | $13.29B | $607.00M | (m) | (m) | 21.89× | Reported |
| 2012-04-01 | (m) | (m) | $642.00M | $14.17B | $593.00M | (m) | (m) | 23.89× | Reported |
| 2012-01-01 | (m) | (m) | $621.00M | $13.77B | $571.00M | (m) | (m) | 24.11× | Reported |
| 2011-10-02 | (m) | (m) | $624.00M | (m) | $526.00M | (m) | (m) | (m) | Reported |
| 2011-07-03 | (m) | (m) | $648.00M | (m) | $500.00M | (m) | (m) | (m) | Reported |
| 2011-04-03 | (m) | (m) | $609.00M | (m) | $472.00M | (m) | (m) | (m) | Reported |
| 2011-01-02 | (m) | (m) | $614.00M | (m) | $455.00M | (m) | (m) | (m) | Reported |
| 2010-10-03 | (m) | (m) | $603.00M | (m) | $410.00M | (m) | (m) | (m) | Reported |
| 2010-07-04 | (m) | (m) | $592.00M | (m) | $444.00M | (m) | (m) | (m) | Reported |
| 2010-04-04 | (m) | (m) | $626.00M | (m) | $453.00M | (m) | (m) | (m) | Reported |
| 2010-01-03 | (m) | (m) | $628.00M | (m) | $451.00M | (m) | (m) | (m) | Reported |
| 2009-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-28 | (m) | (m) | $627.00M | (m) | $435.00M | (m) | (m) | (m) | Reported |
| 2008-09-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-30 | (m) | (m) | $698.00M | (m) | $296.00M | (m) | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |